Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Cisplatin + Veliparib + Vinorelbine |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Cisplatin | Platinol | CDDP | Chemotherapy - Platinum 7 | Platinol (cisplatin) is a platinum based chemotherapeutic, which is FDA approved for bladder, ovarian, and testicular cancers (NCI Drug Dictionary). |
| Veliparib | ABT-888 | PARP Inhibitor (Pan) 29 | Veliparib (ABT-888) is a PARP1 and PARP2 inhibitor, which inhibits DNA repair and induces lethality in homologous recombination deficient cells, and may enhance the sensitivity of chemotherapeutic agents (PMID: 26251615, PMID: 31074636, PMID: 32452601). | |
| Vinorelbine | Navelbine | Vinorelbin | Antimicrotubule Agent 14 | Navelbine (vinorelbine) is a tubulin binding alkaloid that inhibits tubulin polymerization, thus inhibiting spindle formation, leading to apoptosis (NCI Drug Dictionary). Navelbine (vinorelbine) is approved for use in NSCLC (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|